Details

Autor(en) / Beteiligte

• Smart, Jennifer I
• Corey, G. Ralph
• Stryjewski, Martin E
• Wang, Whedy
• Barriere, Steven L

Titel

Assessment of Telavancin Minimal Inhibitory Concentrations by Revised Broth Microdilution Method in Phase 3 Complicated Skin and Skin-Structure Infection Clinical Trial Isolates

Ist Teil von

• Diagnostic microbiology and infectious disease, 2017-03, Vol.87 (3), p.268-271

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2017

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• Abstract The broth microdilution (BMD) minimal inhibitory concentration (MIC) testing method for telavancin was recently revised (rBMD) to improve accuracy and reproducibility. Staphylococcus aureus isolates from telavancin phase 3 complicated skin and skin-structure infection (cSSSI) studies were tested using the rBMD method. Retesting of 1132 isolates produced MICs ranging from ≤0.015 to 0.12 μg/mL that were 8-fold lower than the original method. All isolates tested remained susceptible to telavancin at the revised susceptibility breakpoint of 0.12 μg/mL. The clinical cure and microbiological eradication rates were 90% (368/409) and 89% (366/409) for telavancin-treated patients, and were similar for patients with methicillin-susceptible and resistant S. aureus isolates and S. aureus isolates with elevated vancomycin MICs (≥1 μg/mL). The data presented here is aimed to update the literature and better inform clinicians and clinical microbiologists about the revised telavancin MICs, as well as the corresponding clinical and microbiological cure rates for cSSSI patients.